France · Delayed Price · Currency is EUR Sensorion Company Description
Sensorion SA, a biotechnology company, engages in the development of novel therapies to restore, treat, and prevent hearing loss disorders in France.
The company develops SENS-501, a dual AAV vector gene therapy development product for restoring hearing in patients with mutations in OTOF gene in Phase 1/2 clinical trials; and SENS-601, a candidate for the treatment of hearing loss caused by mutations of the GJB2 gene in preclinical studies.
It is also developing SENS-40, a small molecule in Phase 2b clinical trials to treat sudden sensorineural hearing loss; prevention of residual hearing loss following cochlear implantation in Phase 2a clinical trials; and prevention of cisplatin-induced ototoxicity in Phase 2a clinical trials.
The company was incorporated in 2009 and is headquartered in Montpellier, France.
Contact Details
Address: 375, rue du Professeur Joseph Blayac Montpellier, 34080 France | |
| Phone | 33 4 67 20 77 30 |
| Website | sensorion.com |
Stock Details
| Ticker Symbol | ALSEN |
| Exchange | Euronext Paris |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | EUR |
| ISIN Number | FR0012596468 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Amit D. Munshi M.B.A. | Chairman and Interim Chief Executive Officer |
| Laurene Danon | Chief Financial Officer |
| Bernd Schmidt | Chief Technical Officer |
| Dr. Geraldine Honnet M.D. | Chief Medical Officer |
| Christine Le Bec | Head of CMC Gene Therapy |
| Stephanie Filipe | Head of Business Operations and Portfolio Management |
| Laurent Desire | Head of Preclinical Development |
| Rachel Cooper | Head of Audiology |